Developing Adaptive Personalized Therapy for Cystic Fibrosis using Reinforcement Learning
暂无分享,去创建一个
[1] Karen A Robinson,et al. Pulmonary Perspective Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations , 2009 .
[2] M. Hodson,et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. , 2000, The European respiratory journal.
[3] S. Murphy,et al. An experimental design for the development of adaptive treatment strategies , 2005, Statistics in medicine.
[4] Andrew W. Moore,et al. Reinforcement Learning: A Survey , 1996, J. Artif. Intell. Res..
[5] H Putter,et al. Tutorial in biostatistics: competing risks and multi‐state models , 2007, Statistics in medicine.
[6] M. Kosorok,et al. Reinforcement learning design for cancer clinical trials , 2009, Statistics in medicine.
[7] M. Kosorok,et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition , 2001, Pediatric pulmonology.
[8] R. Kronmal,et al. Advancing outcome measures for the new era of drug development in cystic fibrosis. , 2007, Proceedings of the American Thoracic Society.
[9] J. Kalbfleisch,et al. The Analysis of Panel Data under a Markov Assumption , 1985 .
[10] Karen A Robinson,et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.
[11] J. Emerson,et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis * , 2001, Pediatric pulmonology.
[12] James M. Robins,et al. Optimal Structural Nested Models for Optimal Sequential Decisions , 2004 .
[13] R. Bellman. Dynamic programming. , 1957, Science.
[14] J. Emerson,et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. , 2001, The Journal of infectious diseases.
[15] M. Kosorok,et al. Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer , 2011, Biometrics.
[16] V. Waters,et al. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. , 2008, The Cochrane database of systematic reviews.
[17] A. Smyth,et al. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. , 2006, The Cochrane database of systematic reviews.
[18] Joelle Pineau,et al. Constructing evidence-based treatment strategies using methods from computer science. , 2007, Drug and alcohol dependence.
[19] Carmen Cadarso-Suárez,et al. Multi-state models for the analysis of time-to-event data , 2009, Statistical methods in medical research.
[20] Margaret Rosenfeld,et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. , 2009, Contemporary clinical trials.
[21] S. Rowe,et al. mechanisms of disease Cystic Fibrosis , 2005 .
[22] N. Høiby,et al. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[23] Meenu Singh,et al. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. , 2003, The Cochrane database of systematic reviews.
[24] P. McCray,et al. Pathogenesis of Early Lung Disease in Cystic Fibrosis: A Window of Opportunity To Eradicate Bacteria , 2005, Annals of Internal Medicine.
[25] J. Dankert-Roelse,et al. Newborn screening for cystic fibrosis. , 2009, The Cochrane database of systematic reviews.
[26] Vladimir Vapnik,et al. The Nature of Statistical Learning , 1995 .
[27] Susan A. Murphy,et al. A Generalization Error for Q-Learning , 2005, J. Mach. Learn. Res..
[28] R. Kronmal,et al. Association between pulmonary function and sputum biomarkers in cystic fibrosis. , 2007, American journal of respiratory and critical care medicine.
[29] Vladimir N. Vapnik,et al. The Nature of Statistical Learning Theory , 2000, Statistics for Engineering and Information Science.
[30] C. Watkins. Learning from delayed rewards , 1989 .
[31] R. Gibson,et al. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis , 2007, Pediatric pulmonology.
[32] Massimiliano Mascherini,et al. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients , 2005, European Respiratory Journal.
[33] P. Sly,et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis , 2008, European Respiratory Journal.
[34] R. Gibson,et al. Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.
[35] Joelle Pineau,et al. Adaptive Treatment of Epilepsy via Batch-mode Reinforcement Learning , 2008, AAAI.
[36] Louis Wehenkel,et al. Clinical data based optimal STI strategies for HIV: a reinforcement learning approach , 2006, Proceedings of the 45th IEEE Conference on Decision and Control.
[37] N. Høiby,et al. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment , 1991, The Lancet.
[38] M. Kosorok,et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. , 2005, JAMA.
[39] Alexander J. Smola,et al. Support Vector Method for Function Approximation, Regression Estimation and Signal Processing , 1996, NIPS.
[40] G. Retsch-Bogart. Update on new pulmonary therapies , 2009, Current opinion in pulmonary medicine.
[41] A. Prince. Biofilms, antimicrobial resistance, and airway infection. , 2002, The New England journal of medicine.
[42] F. Ratjen,et al. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis , 2001, The Lancet.
[43] J M Robins,et al. Marginal Mean Models for Dynamic Regimes , 2001, Journal of the American Statistical Association.
[44] Richard S. Sutton,et al. Reinforcement Learning: An Introduction , 2005, IEEE Transactions on Neural Networks.
[45] J. Emerson,et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.
[46] M S Pepe,et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. , 1999, The New England journal of medicine.
[47] P. Farrell,et al. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis , 2003, Pediatric pulmonology.
[48] S. Murphy,et al. Developing adaptive treatment strategies in substance abuse research. , 2007, Drug and alcohol dependence.
[49] Pierre Geurts,et al. Extremely randomized trees , 2006, Machine Learning.
[50] J. Emerson,et al. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis , 1999, Pediatric pulmonology.
[51] N. Høiby,et al. Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay , 1987, Journal of clinical microbiology.
[52] Pierre Geurts,et al. Tree-Based Batch Mode Reinforcement Learning , 2005, J. Mach. Learn. Res..
[53] J. Carlin,et al. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis , 1996, Pediatric pulmonology.
[54] J. Elborn,et al. Clinical trials in cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[55] H. Sung,et al. Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials , 2002 .